Health Care & Life Sciences » Biotechnology | CrystalGenomics Inc.

CrystalGenomics Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
7,863
28,635
26,134
28,040
30,646
Total Accounts Receivable
4,110
3,058
8,525
6,861
3,066
Inventories
-
107
1,270
3,994
517
Other Current Assets
324
435
1,900
798
264
Total Current Assets
12,297
32,236
37,828
39,694
34,493
Net Property, Plant & Equipment
13,864
13,143
24,043
24,477
23,454
Total Investments and Advances
55,508
55,549
57,590
56,243
57,471
Long-Term Note Receivable
58
23
-
-
-
Intangible Assets
6,990
5,207
7,403
7,036
4,027
Other Assets
52
-
421
381
19
Total Assets
88,769
130,968
127,285
128,666
119,465
ST Debt & Current Portion LT Debt
2,499
20,500
25,761
32,001
11,632
Accounts Payable
57
1,596
4,005
2,058
739
Other Current Liabilities
3,564
9,683
8,584
6,177
4,596
Total Current Liabilities
6,120
31,779
38,351
40,236
16,967
Long-Term Debt
32,047
15,849
9,459
1,863
7,800
Provision for Risks & Charges
1,140
1,312
216
512
400
Deferred Taxes
1,818
1,924
1,859
1,291
2,126
Other Liabilities
11,481
2,535
3,760
664
585
Total Liabilities
52,606
78,209
53,646
45,402
27,878
Common Equity (Total)
36,164
52,690
71,941
83,158
91,587
Total Shareholders' Equity
36,164
52,690
71,941
83,158
91,587
Total Equity
36,164
52,690
73,639
83,265
91,587
Liabilities & Shareholders' Equity
88,769
130,968
127,285
128,666
119,465
Accumulated Minority Interest
-
-
1,698
107
-
Non-Equity Reserves
-
69
-
-
-

About CrystalGenomics

View Profile
Address
5/F, Tower A, Korea Bio Park
Seongnam GY 13488
Korea, Republic Of
Employees -
Website http://www.crystalgenomics.com
Updated 09/14/2018
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company operates through following business divisions: Research and Development, New Drug Development division, New Drug Sales, Products Sales, and Real Estate Leasing. The Research and Development division provides analysis of clinical trials services.